Whitepaper: Drug shortages – why do they happen and how can we stop them?
This whitepaper from NSF looks at the key causes of drug shortages and what we can do to stop them.
List view / Grid view
This whitepaper from NSF looks at the key causes of drug shortages and what we can do to stop them.
Researchers have developed a new formulation for cancer vaccines that could provide a solution to its delivery complications.
The results of a clinical study for a gestational malaria vaccine has shown that the treatment is "well tolerated" and can produce an immune response.
Medreich Plc is recalling a number of ranitidine products due to possible contamination with an impurity N-nitrosodimethylamine (NDMA).
Priority review has been given to the NDA for selpercatinib to treat advanced RET fusion-positive non-small cell lung cancer, RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.
Watch Data Scientist Patrick O’Sullivan of Janssen describe how they reduce the amount of time spent preparing data for their million data point systems.
AstraZeneca’s new carbon emission plan includes a 100 percent electric vehicle fleet and a 50 million tree reforestation plan.
A novel formulation for dolutegravir has been developed to improve HIV treatment options for children. Dr Kimberly Smith from ViiV Healthcare discusses the benefits of this new dispersible tablet.
The FDA has granted Investigational New Drug application to PLX-200 to treat late infantile neuronal ceroid lipofuscinosis (LINCL).
EU marketing authorisation has been given to Sunosi (solriamfetol) for excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea.
A study has demonstrated in mice the success of a vaccine design which can be stored at room temperature for long periods of time.
The World Health Organization (WHO) has released new reports which state that a lack of innovation in new antibiotic development is undermining efforts to combat drug-resistant infections.
Researchers have created a unique edible film to be added onto the surface of drugs which can produce a security key, preventing counterfeits from reaching patients.
The US FDA has granted Fast Track Designation to APD418, which is in development as treatment for decompensated heart failure patients.
NICE has asked for more information on Keytruda (pembrolizumab) for untreated metastatic or unresectable recurrent squamous cell head and neck cancer due to uncertainty over clinical trial evidence.